Study @ consisted of a pilot safety phase ( N = @ ) during which subjects received a single body-weight-adjusted subcutaneous dose of lipegfilgrastim @ g/kg and a dose escalation phase ( N = @ ) wherein subjects received lipegfilgrastim @ or @ g/kg or pegfilgrastim @ g/kg .